Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

St Jude Medical gets approval for chronic pain treatment

Tuesday, October 4, 2016 7:33
% of readers think this story is Fact. Add your two cents.

(Before It's News)

St Jude Medical Inc (NYSE:STJ) has received US approval of BurstDR stimulation, a treatment for people with chronic spinal chord (SCS) pain.

The St Paul-based company said BurstDR stimulation had been clinically proven to improve upon traditional SCS therapy by generating superior pain relief. 

BurstDR uses intermittent “burst” pulses designed to mimic the body’s natural nerve impulse patterns.

St Jude introduced it after nearly a decade of research and study in collaboration with Prof. Dirk De Ridder, who filed the therapy’s initial patents in 2004.

Chronic pain affects approximately 1.5bn people worldwide, more than heart disease, cancer and diabetes combined.

“Chronic pain is one of the most costly epidemic diseases facing health care systems worldwide, and one of the most challenging for physicians to manage due to the complexity of the condition and the differences in each patient’s clinical case,” said Allen Burton, medical director of neuromodulation and vice president of medical affairs.

 “With FDA approval of BurstDR stimulation, we are empowering physicians with a new therapy option in their fight against widespread chronic pain.”

St Jude shares edged higher to US$80.18.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.